| 肾细胞癌分子靶向治疗进展 |
| |
| 引用本文： | 林英城,王鸿彪,曾德. 肾细胞癌分子靶向治疗进展[J]. 国外医学(肿瘤学分册), 2007, 0(4) |
| |
| 作者姓名： | 林英城 王鸿彪 曾德 |
| |
| 作者单位： | 汕头大学医学院附属肿瘤医院内科，汕头大学医学院附属肿瘤医院内科，汕头大学医学院附属肿瘤医院内科 |
| |
| 摘 要： | 针对血管内皮生长因子受体和表皮生长因子受体信号传导通路发展的低分子量多靶点酪氨酸激酶抑制剂、抗血管生成单克隆抗体、哺乳动物雷帕霉素靶蛋白抑制剂等分子靶向药物二线治疗肾细胞癌有延长无进展生存优势;一线治疗在无进展生存期及总生存期方面优于传统细胞因子治疗。分子靶向药物联合应用及与细胞因子或传统化疗药物的联合应用正在研究中。
|
| 关 键 词： | 肾肿瘤 受体蛋白质酪氨酸激酶类 血管生成抑制剂 药物疗法 |
Molecular targeted therapy for renal cell cancer |
| |
| LIN Ying-cheng WANG Hong-biao ZENG De. Medical. Molecular targeted therapy for renal cell cancer[J]. Foreign Medical Sciences (Cancer Section), 2007, 0(4) |
| |
| Authors: | LIN Ying-cheng WANG Hong-biao ZENG De. Medical |
| |
| Affiliation: | LIN Ying-cheng WANG Hong-biao ZENG De. Medical Department of Oncology,Cancer Hospital,Shantou University Medical College,Shantou 515031,China |
| |
| Abstract: | Multitargeted small molecular tyrosine kinases inhibitor that target vascular endothelial growth factor receptor(VEGFR)and epidermal growth factor receptor(EGFR),antiangiogenic monoclonal anti- body and mammalian target of rapamycin(mTOR)inhibitor have all shown prolonged progression-free survival as second-line therapy for renal cell cancer(RCC).The progression-free survival and overall survival in molec- ular target therapy are now proven to be better than cytokine therapy in the first-line therapy of advanced RCC. The study evaluating combinations of different molecular targeted agents and molecular targeted agents combined with cytokine or chemotherapy agents are ongoing. |
| |
| Keywords: | Kidney neoplasms Receptor protein-tyrosine kinases Angiogenesis inhibitors Drug therapy |
| 本文献已被 CNKI 等数据库收录！ |
